Morten Schou, MD, PhDCredit: LinkedInAn analysis of the STEP-HFpEF program suggests use of semaglutide 2.4 mg (Wegovy) could help prevent deterioration, and possibly improve,...
Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and...